Abstract : A sixty-six year-old patient with liver cirrhosis and diabetes was nutritionally treated by administration of the low glycemic index liquid food (Inslow) as a late evening sack (LES) for 6 weeks. The mean energy intake increased from 825 48 kcal/d to 1567 66 kcal/d after the 6-week treatment period. The fasting glucose level did not change, remaining at about 100 mg/dl throughout this period. Interestingly, the amount of insulin administered was reduced from 38 units before treatment to 28 units in the fifth week of treatment without a change in the fasting glucose level. This indicates a marked improvement in insulin sensitivity due to Inslow administration in this patient. In conclusion, the long-term administration of Inslow as an LES may be an effective treatment for cirrhotic patients.
INTRODUCTION
The nutritional state of patients with liver cirrhosis is frequently poor, and about 70% of patients show some signs of malnutrition (1) . Patients with liver cirrhosis exhibit abnormal metabolism, including increased fat oxidation and decreased glucose oxidation (2) (3) (4) . Increased fat oxidation manifests as starvation after an overnight fast because of a lack of glycogen stores in patients (5) . Furthermore, liver cirrhosis frequently impairs postprandial glucose tolerance, with 20 to 40% of patients developing diabetes mellitus. Therefore, supplementation of a late evening snack (LES) with a low glycemic index (GI) may be advisable in such patients to prevent early-onset starvation and energy deficiency and to maintain a good nutritional status.
The GI was introduced by Jenkins, et al. as a quantitative assessment of foods based on the postprandial blood glucose response (6, 7) , and is expressed as a percentage of the response to an equivalent carbohydrate portion of a reference food, such as white bread or glucose (8) . The novel enteral liquid formula designated Inslow was prepared by replacing dextrin in the standard balanced formula (SBF) with palatinose at 55.7% of the carbohydrate content (Table 1) . Palatinose was completely cleaved and absorbed, and the hydrolysis of palatinose by a homogenate of human intestinal mucosa was one-fourth that of sucrose (9, 10) . A previous study in our laboratory demonstrated that the increase in plasma glucose and insulin after Inslow ingestion was significantly smaller than that after SBF ingestion (11, 12) . In this study, because lack of energy intake was assessed in a patient with liver cirrhosis and diabetes controlled with insulin, 250 kcal of Inslow was administered.
PROCEEDING
Nutritional treatment of a patient with hepatic cirrhosis with the novel low glycemic index liquid food (Inslow) The daily pattern of blood glucose fluctuated highly in the initial period of nutritional treatment, but interestingly blood glucose levels became constant in the fifth week of treatment (Fig. 2) . The cumulative area under the curve (AUC) for daily blood glucose in the fifth and sixth weeks of nutritional treatment was significantly lower than that in the first and second weeks (Fig. 3) . Laboratory data, including serum levels of albumin, α-fetoprotein and protein induced by vitamin K absence of antagonist-II (PIVKA-II), lactate dehydrogenase activity and other biomarkers of hepatic function and nutritional status, did not show any significant changes after this nutritional treatment (Table 2) . 
DISCUSSION
Characteristic hormonal and metabolic alterations, including depleted hepatic glycogen storage and impaired hepatic glycogenolysis, have been shown in cirrhotic subjects (14) (15) (16) (17) (18) ). An LES has been shown to improve fuel utilization (19, 20) and nitrogen economy (21, 22 ). An LES comprising a liquid nutrient (Ensure Liquid) has also been shown to increase RQ and carbohydrate oxidation rates (23) . For these reasons, LES administration was recommended to minimize early starvation for overnight fasting in this patient because of an insufficient energy intake.
Cirrhotic patients usually exhibit postprandial hyperglycemia and hyperinsulinemia. Depending on the etiology, degree of liver damage and diagnostic criteria, the reported incidence of impaired glucose tolerance in liver cirrhosis varies between 60 and 80% and that of diabetes varies between 20 and 63% (24) . Studies using the 'euglycemic hyperinsulinemic glucose clamp technique' show that nearly all patients with cirrhosis have peripheral insulin resistance at 30-60% of the control level (25, 26) . Peripheral insulin resistance in cirrhosis is characterized by decreased glucose transport and reduced glycogen synthesis in skeletal muscle, whereas the insulininduced increases in glucose phosphorylation, glycolysis and glucose oxidation are normal in cirrhosis (27) (28) (29) (30) . Similarly, the increased amounts of insulin cannot normalize the capacity of glycogen synthesis, but disproportionally increase lactate production in cirrhosis (29) .
The energy intake of this patient increased from 825 kcal to 1567 kcal through nutritional therapy with the low GI food Inslow as an LES for 6 weeks. In contrast, the amount of insulin injected decreased from 38 units to 28 units, indicating a marked improvement in insulin sensitivity due to Inslow administration. These findings may explained by our previous data showing that Inslow suppressed postprandial hyperglycemia and reduced hepatic and visceral fat accumulation better than another commercially available SBF, despite the fact that the daily food intake remained the same in both groups over the long term (11) . Furthermore, expression of the PPAR-γ and adiponectine genes in the adipose tissue was higher in the Inslow group than in the SBF group (31) . The PPAR-γ is a major regulator of adipocyte differentiation and controls the expression of various kinds of adipocyte-specific genes (32) . Pharmacological activators of PPAR-γ, such as thiazolidinedione (TZD), significantly improve insulin sensitivity in type 2 diabetes (33). Furthermore, Inslow enhanced expression of the β-oxidation enzyme gene in adipose tissue. Therefore, it was suggested that Inslow promotes an insulin-sparing effect, raises the number of small adipocytes, and increases the expression of PPAR-γ mRNA to stimulate fatty acid utilization.
Inslow supplementation as an LES for 6 weeks did not improve the laboratory data of hepatic function and nutritional status. However, we conclude that the long-term administration of Inslow as an LES may be a useful and novel treatment for increasing energy intake and improving insulin resistance in cirrhotic patients, although further studies are required.
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